Osteosarcoma: Clinical Trials

5 trials for Osteosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 withdrawn. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Withdrawn 5
Phase 11Withdrawn 1

Follow Osteosarcoma: new trials by email Literature Review of Osteosarcoma trials Research Report on Osteosarcoma

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin - Solid Tumors, Soft Tissue Sarcoma
Phase 2WithdrawnChildren's National Research Institute2022-11-102025-01-01
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma
Phase 2WithdrawnBrown University2022-03-012021-12-07
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride - Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2021-09-152022-02-10
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Erlotinib, Temozolomide - Glioma, Rhabdomyosarcoma
Phase 2WithdrawnWashington University School of Medicine2016-08-062019-09-09
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Imetelstat Sodium, Laboratory Biomarker Analysis - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma
Phase 2WithdrawnChildren's Oncology Group2014-06-302018-08-07

Narrower conditions

Rhabdomyosarcoma (4)  ·  Sarcoma, Ewing (3)  ·  Sarcoma (2)  ·  Wilms Tumor (2)  ·  Bone Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Dermatofibrosarcoma (1)  ·  Ependymoma (1)  ·  Glioma (1)  ·  Hemangiosarcoma (1)  ·  Hepatoblastoma (1)  ·  Histiocytoma, Malignant Fibrous (1)  ·  Leiomyosarcoma (1)

Broader conditions

Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Neoplasms, Bone Tissue (5)  ·  Neoplasms, Connective Tissue (5)  ·  Neoplasms, Connective and Soft Tissue (5)  ·  Myosarcoma (4)  ·  Neoplasms, Muscle Tissue (4)  ·  Neoplasms by Site (3)  ·  Neoplasms, Complex and Mixed (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Sarcoma (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Genetic Diseases, Inborn (2)

Interventions

3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1)  ·  Biopsy, Fine-Needle (1)  ·  Docetaxel (1)  ·  Erlotinib Hydrochloride (1)  ·  GRN163L peptide (1)  ·  Gemcitabine (1)  ·  Irinotecan (1)  ·  PM 01183 (1)  ·  Temozolomide (1)  ·  imetelstat (1)

Sponsors

Brown University (1)  ·  Children's National Research Institute (1)  ·  Children's Oncology Group (1)  ·  M.D. Anderson Cancer Center (1)  ·  Washington University School of Medicine (1)

Countries

United States (3)

Top investigators

AeRang Kim, MD, PhD (1)  ·  Alok Kothari, M.D. (1)  ·  Bradley D DeNardo, MD (1)  ·  Galina G Lagos, MD (1)  ·  Patrick Thompson (1)  ·  Robert S Benjamin (1)

Results publications

PMID 31401903

NIH funding

U10CA098543 (1)